Core Viewpoint - Vitiligo is a complex autoimmune disease with no clear treatment options, affecting approximately 30 million people in China, with a significant portion of patients experiencing anxiety and depression due to the condition [3][4]. Treatment Landscape - Current treatment methods for vitiligo in China are limited, primarily involving topical corticosteroids and calcineurin inhibitors, which only suppress immune responses and do not promote repigmentation or prevent relapse [4]. - The FDA has approved the JAK inhibitor ruxolitinib cream for the treatment of non-segmental vitiligo in patients aged 12 and older, but it is not yet available in China and cannot be used for children under 12 [5]. Market Potential - The market for innovative vitiligo treatments in China is projected to reach 120 billion to 259 billion yuan under conservative to optimistic scenarios, indicating a significant opportunity for new products [6]. - The current pipeline for vitiligo treatments is not overly crowded, suggesting that successful new therapies that balance safety and efficacy could quickly gain market share due to unmet clinical needs [6]. Research and Development - Several domestic pharmaceutical companies are actively developing new treatments for vitiligo, including new JAK inhibitors and innovative approaches like the CKBA ointment being developed by TianKang, which targets T-cell fatty acid metabolism [5][6]. - TianKang has reported promising results from the Phase II clinical trials of CKBA ointment and is advancing to Phase III trials while seeking breakthrough therapy designation from the National Medical Products Administration [5].

Group 1 - The stock price of TianKang as of August 14, 2025, is 35.24 yuan, down by 1.02 yuan or 2.81% from the previous trading day [1] - The opening price on the same day was 36.25 yuan, with a highest point of 36.41 yuan and a lowest point of 35.15 yuan, with a trading volume of 59,400 hands and a transaction amount of 211 million yuan [1] - On August 14, the net outflow of main funds from TianKang was 36.64 million yuan, accounting for 0.34% of the circulating market value [1] Group 2 - Over the past five trading days, the cumulative net outflow of main funds reached 146 million yuan, representing 1.36% of the circulating market value [1] - TianKang operates in the pharmaceutical commercial sector, with its main business covering pharmaceutical product agency, research and development, and production, including areas such as hair medical treatment [1]

Group 1 - The stock price of TianKang as of August 12, 2025, closed at 35.98 yuan, down 0.96% from the previous trading day, with a trading volume of 63,031 hands and a transaction amount of 226 million yuan [1] - TianKang's main business includes the research, production, and sales of pharmaceutical products. The company recently hosted a summit on innovative immunotherapy clinical transformation research, focusing on cutting-edge developments in the field of immunotherapy [1] - Chairman Zheng Hanjie stated at the summit that China's innovative drug industry is transitioning from "catching up" to "running alongside" and even "leading" [1] Group 2 - On the evening of August 12, the company announced a change in its continuous supervision sponsor representative, with Wang Ning replacing Liu Xiangmao to continue the supervision work [1] - The global pioneering small molecule drug CKBA, which the company is involved in developing, received attention at the summit. This drug targets the treatment of skin diseases such as vitiligo [1]

（编辑 姚尧） 证券日报网讯 8月12日晚间，泰恩康发布公告称，公司于近日收到国泰海通证券股份有限公司（简 称"国泰海通"）出具的《关于变更广东泰恩康医药股份有限公司持续督导保荐代表人的函》。国泰海通 作为公司首次公开发行股票并在创业板上市的保荐机构，原委派刘祥茂先生、徐振宇先生作为项目保荐 代表人。原保荐代表人刘祥茂先生因工作变动，不再继续担任公司持续督导期间的保荐代表人，为保证 持续督导工作的有序进行，国泰海通决定委派保荐代表人王宁先生接替刘祥茂先生继续履行持续督导工 作。 ...

国浩律师（深圳）事务所 关于 广东泰恩康医药股份有限公司 2025 年员工持股计划 之 法律意见书 深圳市深南大道 6008 号特区报业大厦 24、31、41、42 楼 邮编：518034 24/F、31/F、41/F、42F, Tequbaoye Buliding, 6008 Shennan Avenue, Shenzhen, Guangdong Province 518034, China 电话/Tel: (+86)(755) 8351 5666 传真/Fax: (+86)(755) 8351 5333 网址/Website: http://www.grandall.com.cn 二〇二五年八月 国浩律师（深圳）事务所 法律意见书 国浩律师（深圳）事务所 关于广东泰恩康医药股份有限公司 2025 年员工持股计划之 法律意见书 编号: GLG/SZ/A4793/FY/2025-962 国浩律师（深圳）事务所 法律意见书 致：广东泰恩康医药股份有限公司 国浩律师（深圳）事务所（以下简称"本所"）接受广东泰恩康医药股份有 限公司（以下简称"泰恩康"或"公司"）的委托，担任公司 2025 年员工持股 计划（以下简 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-052 董事会 2025 年 8 月 12 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于近日收到国泰海通证 券股份有限公司（以下简称"国泰海通"）出具的《关于变更广东泰恩康医药股 份有限公司持续督导保荐代表人的函》。国泰海通作为公司首次公开发行股票并 在创业板上市的保荐机构，原委派刘祥茂先生、徐振宇先生作为项目保荐代表人， 负责保荐工作及持续督导工作，持续督导期至 2025 年 12 月 31 日止。 原保荐代表人刘祥茂先生因工作变动，不再继续担任公司持续督导期间的保 荐代表人，为保证持续督导工作的有序进行，国泰海通决定委派保荐代表人王宁 先生接替刘祥茂先生继续履行持续督导工作（王宁先生简历详见附件）。 本次保荐代表人变更后，公司持续督导保荐代表人为徐振宇先生、王宁先生， 持续督导期至中国证券监督管理委员会和深圳证券交易所规定的持续督导义务 结束为止。 本次变更持续督导保荐代表人的事项不会对公司的生产经营活动造成任何 风险和影响。公司董事会对刘 ...

Investment Rating - The industry investment rating is "Outperform the Market" [1][47]. Core Insights - The white spot market for vitiligo treatment is vast, with a potential market size expected to reach 21.7 billion yuan by 2030, driven by an increasing number of patients and the need for effective treatments [3][15][39]. - Current treatment options are inadequate, with no approved products specifically for vitiligo in China, highlighting a significant gap in the market that innovative drugs could fill [3][26]. - The competitive landscape is favorable, with several small pharmaceutical companies and leading firms vying for market share, and key products expected to receive approval soon [3][39]. Summary by Sections Part 1: Patient Demographics and Health Risks - The prevalence of vitiligo is significant, with approximately 22.83 million patients in China, of which 54.01% are receiving treatment [3][15]. - The condition is associated with severe psychological impacts, including a higher incidence of depression among patients [3][10]. Part 2: Current Treatment Limitations - Existing treatments, primarily involving drug therapy and phototherapy, have shown limited effectiveness, necessitating the introduction of new drugs with higher repigmentation rates [3][24]. - The current market lacks approved medications specifically for vitiligo, with existing drugs primarily approved for other conditions [3][26]. Part 3: Competitive Landscape and Drug Development - The vitiligo treatment sector is characterized by a lack of approved products, with several drugs in various stages of clinical trials, including one in Phase III and six in Phase II [3][39]. - JAK inhibitors are identified as key targets in drug development, with the first approved topical JAK1/JAK2 inhibitor, Ruxolitinib cream, showing promising sales growth [3][32][39]. - The innovative drug market for vitiligo is projected to reach 10 billion yuan, with significant interest in companies like Kangzheng Pharmaceutical and TianKang [3][39]. Part 4: Investment Recommendations - The report suggests focusing on the progress of drug development in the vitiligo sector and monitoring companies involved, including Kangzheng Pharmaceutical, TianKang, Huadong Medicine, and others [3][39].

Core Insights - The Chinese innovative drug development landscape has significantly evolved over the past decade, transitioning from imitation to innovation, particularly in the field of immunotherapy [1][2][3] - China has become the world's second-largest innovative drug development base, with a projected outbound transaction value of innovative drugs reaching between $48.4 billion and $66 billion by mid-2025, accounting for over 30% of global business development transactions [2] - The approval rate of drugs entering clinical stages by the FDA is notably high, with half of these drugs originating from China, either through direct applications or acquisitions by major U.S. companies [2] Industry Developments - The first Shantou Health Expo highlighted advancements in innovative immunotherapy, attracting over a hundred participants from various sectors, including government, academia, and investment [1] - The shift from "following" to "running alongside" and even "leading" in the innovative drug industry is attributed to supportive national policies, technological breakthroughs, and deepening global collaborations [1][2] - The importance of high-quality clinical research, patient education, and private investment in drug development is emphasized as critical for the success of innovative drugs [3] Drug-Specific Innovations - CKBA, a first-in-class small molecule drug developed in collaboration with the Tianenkang team, shows promise in treating vitiligo by modulating T cell metabolism and reducing the risk of relapse [4][5] - The drug's efficacy and safety have been highlighted, particularly in pediatric patients, with expectations for its market release following successful phase III trials [5] - The potential for CKBA to address other inflammatory skin diseases, such as rosacea, is also noted, with a focus on its targeted action on the Th17 pathway [5][6] Future Directions - The need for international clinical validation of Chinese innovative drugs is stressed to enhance their commercial value, leveraging China's patient resources and clinical efficiency [6] - There is a call for better collaboration between academia, industry, and healthcare to transform clinical ideas into viable drug development projects [6] - The exploration of traditional Chinese medicine's active components for modern drug development is seen as a promising avenue for future research [3][6]

Group 1 - The core viewpoint of the article highlights the performance of the 中证2000ETF嘉实 (159535), which opened with a decline of 0.45% at 1.337 yuan [1] - The fund's performance benchmark is the 中证2000 index return, managed by 嘉实基金管理有限公司, with a return of 34.32% since its establishment on September 14, 2023, and an 8.90% return over the past month [1] Group 2 - The top holdings of 中证2000ETF嘉实 (159535) include stocks such as 每日互动, 汉威科技, 宏创控股, 东土科技, 恒宝股份, 台基股份, 热景生物, 仕佳光子, 泰恩康, and 益方生物, with varying performance on the opening day [1] - Specific stock performances on the opening day include 每日互动 down 0.72%, 汉威科技 down 0.02%, 宏创控股 up 0.06%, 东土科技 up 0.31%, 恒宝股份 down 0.54%, 台基股份 up 0.44%, 热景生物 down 0.75%, 仕佳光子 down 0.81%, 泰恩康 up 0.03%, and 益方生物 down 1.86% [1]

Core Viewpoint - China's innovative pharmaceuticals have transitioned from being followers to key players in global medical innovation, achieving significant breakthroughs in core treatment areas such as metabolic diseases and oncology, with a surge in new drug approvals and international progress [1][3]. Group 1: Market Trends - The attention of A-share investors towards innovative pharmaceuticals has significantly increased this year, with numerous companies actively disclosing their R&D and clinical progress [2]. - The total value of license-out transactions for innovative drugs in China is projected to exceed $60 billion by mid-2025, surpassing the total for 2024, with 16 transactions exceeding $1 billion each [3]. - The market size of China's innovative drugs reached 679 billion yuan in 2022, expected to exceed 1 trillion yuan by 2026 and reach 1.12 trillion yuan by 2027 [6]. Group 2: International Expansion - Chinese innovative drug companies are accelerating their international business, with 81 companies generating over 100 billion yuan in overseas revenue from 2022 to 2024, accounting for more than 14% of their total revenue [7]. - The proportion of China's innovative drug transactions in the global market has increased from 10.8% in 2015 to approximately 52.5% by August 2023 [6]. Group 3: Policy and Financial Support - The Chinese government has implemented policies to support the high-quality development of innovative drugs, significantly reducing the time from drug approval to inclusion in the medical insurance directory from about 5 years to approximately 1 year [8]. - From 2015 to 2024, the financing in China's innovative drug sector exceeded 1.23 trillion yuan, providing strong momentum for industry growth [9]. Group 4: R&D Investment - The number of companies in the pharmaceutical and biotechnology sector has increased from over 220 in 2015 to nearly 500 currently, with R&D investment in the sector exceeding 140 billion yuan in 2024, a fivefold increase since 2015 [9]. - Among the 81 innovative drug companies, R&D investment rose from approximately 8.8 billion yuan in 2015 to over 57.8 billion yuan in 2024, with R&D intensity increasing from 3.29% to 8.04% [9]. Group 5: Company Developments - Companies such as Betta Pharmaceuticals and Rundu Co. have reported significant advancements in their innovative drug pipelines, with Betta's drug expected to be approved by June 2025 and Rundu's drug completing phase III clinical trials [12]. - The stock performance of companies involved in innovative drugs has surged, with some companies experiencing average increases of over 50% since May 1, 2023 [13]. Group 6: Institutional Interest - 13 companies have received significant institutional interest this year, with some experiencing over 30% increase in financing, indicating strong market confidence in innovative drug investments [14]. - Companies like BeiGene and TaiGen Biotechnology are projected to see substantial profit growth in 2025 and 2026, with BeiGene potentially turning profitable this year [15].